LearnGlossaryMarketStocksSuperinvestorsSign in

ARQT

Arcutis Biotherapeutics, Inc.

Healthcare · $3.4B market cap

Verdict

We can't put a fair value on ARQT right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-33.2% a year✗
Sales growth151.2% a year✓
Free cash flow growth—?
Return on invested capital-44.5%✗

Follow ARQT

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 8, 2026: no open-market purchases and 1 sale worth $250K. Why purchases matter

Sales

Matsuda Masaru

See Remarks · 2026-09-08

Sold

$250K

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works